IntelGenx Technologies Corp. (OTCMKTS:IGXT) CFO Andre Godin acquired 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The stock was bought at an average cost of $0.72 per share, with a total value of $14,400.00. Following the acquisition, the chief financial officer now owns 79,500 shares in the company, valued at $57,240. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
IntelGenx Technologies Corp. (OTCMKTS:IGXT) opened at 0.79 on Wednesday. The company has a 50 day moving average price of $0.78 and a 200 day moving average price of $0.60. The stock’s market cap is $50.26 million. IntelGenx Technologies Corp. has a 52 week low of $0.37 and a 52 week high of $1.00.
IntelGenx Technologies Corp. (OTCMKTS:IGXT) last issued its earnings results on Thursday, August 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.01). IntelGenx Technologies Corp. had a negative net margin of 2.38% and a negative return on equity of 2.57%. Analysts expect that IntelGenx Technologies Corp. will post $0.01 EPS for the current fiscal year.
IGXT has been the subject of several recent analyst reports. HC Wainwright set a $2.00 price target on IntelGenx Technologies Corp. and gave the company a “buy” rating in a research note on Thursday, September 15th. Zacks Investment Research upgraded IntelGenx Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, June 7th.
IntelGenx Technologies Corp. Company Profile
IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.
Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.